Format

Send to

Choose Destination
Neuropharmacology. 2018 Jul 1;136(Pt B):196-201. doi: 10.1016/j.neuropharm.2017.11.037. Epub 2017 Nov 24.

Intranasal insulin in Alzheimer's disease: Food for thought.

Author information

1
Department of Neuroscience, Uppsala University, SE-751 24 Uppsala, Sweden. Electronic address: colin.chapman@neuro.uu.se.
2
Department of Neuroscience, Uppsala University, SE-751 24 Uppsala, Sweden.
3
Department of Pharmacology, Physiology and Neuroscience, University of South Carolina - School of Medicine, Columbia, SC 29209, USA.

Abstract

Accumulating evidence suggests that disrupted brain insulin signaling promotes the development and progression of Alzheimer's disease (AD), driving clinicians to target this circuitry. While both traditional and more modern antidiabetics show promise in combating insulin resistance, intranasal insulin appears to be the most efficient method of boosting brain insulin. Furthermore, intranasal delivery elegantly avoids adverse effects from peripheral insulin administration. However, there remain significant open questions regarding intranasal insulin's efficacy, safety, and potential as an adjunct or mono-therapy. Thus, this review aims to critically evaluate the present evidence and future potential of intranasal insulin as a meaningful treatment for AD. This article is part of the Special Issue entitled 'Metabolic Impairment as Risk Factors for Neurodegenerative Disorders.'

KEYWORDS:

Alzheimer's disease; Brain insulin resistance; Cognition; Intranasal insulin; Neurodegeneration

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center